Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Wechter, N
Why this trial matters: First bispecific + CD38 combo to show superior PFS and OS in Phase III in RRMM Potential new standard of care as early as second-line Demonstrates deep responses, high MRD-negativity, and durable outcomes First-line Strategies in BRAF V600E-Mutant mCRC: Real-World Evidence Signals Treatment Priorities In a real-world retrospective cohort of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), frontline chemotherapy plus anti-VEGF therapy was associated with the longest survival outcomes, while BRAF-targeted strategies showed promising response rates, emphasizing the need for tailored therapy and prospective validation
Parkinson's disease
Too little creates weak repair, too much causes re-injury
At the 10mg format, this precision is delivered with the research capacity required for full dose-response protocols, multi-arm experimental designs, and the single-batch consistency that longitudinal studies demand
This may include functional assessments, imaging studies, and validated outcome measures
US$ 28.31
US$ 23.43
US$ 28.47
